Five Prime Therapeutics, Inc. appointed Linda Rubinstein as Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer while FivePrime conducts its ongoing search for a new Chief Financial Officer. Ms. Rubinstein will serve in such positions until her successor is appointed or until Ms. Rubinstein's earlier resignation or removal. Ms. Rubinstein, 51, has been a partner at FLG Partners since September 2010 and has served as consulting Chief Financial Officer for multiple clients for FLG Partners.

From February 2013 to October 2013, Ms. Rubinstein served as Chief Financial Officer of PaxVax, Inc. Prior to PaxVax, Ms. Rubinstein served as Senior Vice President and Chief Financial Officer of Ingenuity Systems, Inc. from November 2010 until its acquisition by QIAGEN N.V. in April 2013. From August 2001 to August 2010, Ms. Rubinstein served as the sole principal at RDJ Advisors, a financial and strategic consulting firm. Prior to RDJ Advisors, Ms. Rubinstein served in various operational, financial and capital markets-focused positions at life sciences and SaaS companies and investment banks, including Solexa, Inc.